Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺复方制剂用于性侵犯后暴露后预防：一项回顾性真实世界研究

阅读：1
作者：Teresita de Jesús,Cabrera-López,Edgar,Pérez-Barragán,Carlos Ruben,Nava-Campos,Marla,Toiber-Rodríguez,Juan Carlos,Rodríguez-Aldama,Raúl Adrián,Cruz-Flores,Andrea,González-Rodríguez
期刊：Open Forum Infectious Diseases影响因子：3.800
时间：2024起止号：2024 Aug;11(8):ofae436
doi：10.1093/ofid/ofae436

Abstract

We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。